Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Non-alcoholic Fatty Liver Disease 1Carcinoma, Hepatocellular 1

Interventions

durvalumab 18Bevacizumab 17atezolizumab 13lenvatinib 10Magnetic Resonance Spectroscopy 10tremelimumab 8Nivolumab 8pembrolizumab 7Sorafenib 6Specimen Handling 5camrelizumab 4cabozantinib 4Immunoglobulin G 4Disulfides 4sintilimab 3apatinib 3X-Rays 3Radiotherapy 3Radiofrequency Ablation 3Radiation 3Hepatectomy 3E-7386 3Doxorubicin 3Cyclophosphamide 3tislelizumab 2relatlimab 2dostarlimab 2budigalimab 2Standard of Care 2Simvastatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Hepatocellular × Lisinopril × Clear all
NCT04550481 2026-01-21

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Northwestern University

Phase 2 Active not recruiting
45 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡